Your healthcare provider will typically start your treatment at a low dose of semaglutide (0.25 mg once weekly) and gradually increase the dose every 4 weeks to reduce the risk of gastrointestinal side effects
[DOI] [PubMed] [Google Scholar] 63.Jendle J., Birkenfeld A.L., Polonsky W.H., Silver R., Uusinarkaus K., Hansen T., Hkan-Bloch J., Tadayon S., Davies M.J
Data availability Details of the search strategy and list of identified articles can be found at Abbreviations BGM: Blood glucose monitoring CGM: Continuous glucose monitoring CSII: Continuous subcutaneous insulin infusion CVOT: Cardiovascular outcomes trial DKA: Diabetic ketoacidosis DPP-4i: Dipeptidyl peptidase-4 inhibitors DSMES: Diabetes self-management education and support ETD: Estimated treatment difference GIP: Glucose-dependent insulinotropic polypeptide GLP-1 RA: Glucagon-like peptide-1 receptor agonist(s) HF: Heart failure HHF: Hospitalisation for heart failure MACE: Major adverse cardiovascular events MNT: Medical nutrition therapy NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis SGLT1i: Sodiumglucose cotransporter-1 inhibitor SGLT2i: Sodiumglucose cotransporter-2 inhibitor(s) TZD: Thiazolidinedione UACR: Urinary albumin/creatinine ratio References Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS et al (2016) Shared decision making in endocrinology: present and future directions
[DOI] [PMC free article] [PubMed] [Google Scholar] 621.Sacre JW, Franjic B, Jellis CL, et al
In another real-world analysis of 945 patients, those on tirzepatide lost an average of 6.6 kg versus 3.1 kg on semaglutide over six months
